Huons Global reported consolidated sales of 190.6 billion won ($142.9 million) and operating income of 31.9 billion won ($24 million) for the third quarter of this year, up 13.8 percent and 75 percent, respectively, from the same period last year. The group's performance was driven by increased inte
GC said it has signed a contract manufacturing organization (CMO) contract for Euvichol, an oral cholera vaccine developed by EuBiologics Co.Under the agreement, GC will be responsible for the contract manufacturing of the finished drug product (DP) of Euvichol until 2026. The two companies also set
Hugel announced Monday that it has recorded 84.8 billion won ($64 million) in sales, 34.6 billion won ($26.1 million) in operating profit and 41.6 billion won ($31.4 million) in net profit for the third quarter of 2023 based on consolidated financial statements.Sales and operating income grew 20 per
Aptabio Therapeutics, a developer of intractable cancer and diabetes complications, announced Monday that it will present preclinical results on the effectiveness of its treatment for Parkinson's disease, APX-NEW, in animal models at the Society of Neuroscience (SFN).The SFN is a large-scale meeting
LG Chem has signed a technology transfer agreement with Peptron to tap into the market for prostate cancer and precocious puberty treatment.Peptron said in a public filing last Friday that it signed a contract with LG Chem for the domestic distribution rights of its prostate cancer and sexual precoc
The global medical community is abuzz with anticipation as the first gene-editing therapy nears potential FDA approval in December.According to industry watchers, the gene-editing therapy Exa-cel, co-developed by CRISPR Therapeutics and Vertex Pharmaceuticals, is nearing potential FDA approval in De
SK biopharmaceuticals said the U.S. patent protection for its epilepsy drug Xcopri (ingredient: cenobamate) has been extended for five years until October 30, 2032.Xcopri acquired a substance patent in Oct. 2007 and received new drug approval in the U.S. in Nov. 2019, with the drug officially being
Leclaza, Yuhan Corp.’s homegrown third-generation EGFR mutation-targeted therapy seeking global advances, has also demonstrated that it is effective on patients whose lung cancer has metastasized to the brain.The result of a sub-analysis that separately analyzed the effectiveness of Leclaza’s first-
Medytox won a lawsuit against the Ministry of Food and Drug Safety (MFDS) in a three-year battle over the product approval cancellation of its Meditoxin lineup, its botulinum toxin (BTX) product, for alleged use of unauthorized raw materials.According to Medytox, the Daejeon District Court ruled in
Korea Pharma said Thursday that it has submitted a new product license application to the Ministry of Food and Drug Safety (MFDS) for Methydur SR Cap (methylphenidate hydrochloride), a 24-hour long-acting treatment for attention deficit hyperactivity disorder (ADHD).Methydur is a treatment for ADHD
Despite a remarkable surge in the sales of its flagship product, Xcopri, an epilepsy drug, in the U.S., SK biopharmaceuticals is still facing an operating loss, which raises concerns about the company's financial health.In the third quarter, Xcopri achieved record-breaking sales of 75.7 billion won
Chong Kun Dang Pharmaceutical (CKD Pharm) said Thursday it has released the renewed versions of Lipilow 20mg, 40mg, and 80mg, a treatment for dyslipidemia, after reducing their sizes.Compared to the previous formulations, the new products have been reduced in size by 28 percent for 20mg and 80mg and
Amid recent performance struggles, GC, one of Korea's leading pharmaceutical companies and vaccine makers, has initiated significant steps to restructure its organization and workforce.According to industry officials, GC has started accepting early retirement program (ERP) applications from employee
Kolon Pharma said it has signed a joint development agreement with GBiologics to develop a new drug for systemic lupus erythematosus that seeks to suppress B cells and plasmacytoid dendritic cells (pDC) simultaneously. Under the accord, both companies plan to conduct joint research and development f
The Korea Health Industry Development Institute (KHIDI) announced Wednesday that it is openly recruiting companies to participate in the Korea Startup/Biopharma Acceleration Program 2023, which provides opportunities for Korean startups or biopharmaceutical companies to collaborate with Japanese pha
Gilead Sciences Korea is seeking insurance coverage of its new drug Trodelvy (ingredient: sacituzumab govitecan) for the treatment of triple-negative breast cancer (TNBC).Speaking at a press conference celebrating the launch of the drug at the Plaza Hotel on Tuesday, the company said that it is curr
HK inno.N's indigenously developed drug K-CAB (tegoprazan) has been recognized as an outstanding technology that has contributed to the development of the Korean industry. On Tuesday, HK inno.N announced that K-CAB, a new drug for gastroesophageal reflux disease (GERD), has been selected as an outst
SK chemicals said it reported sales of 296.3 billion won ($226.3 million) and an operating profit of 23.9 billion won ($18.3 million) in the third quarter. Compared to a year earlier, sales and operating profit decreased by 8.6 percent and 30.8 percent, respectively.By business division, the green c
Orum Therapeutics said it has agreed to transfer all rights on ORM-6151, an acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome treatment candidate, to Bristol Myers Squibb (BMS) in a $180 million deal.Under the accord, BMS will pay Orum Therapeutics an upfront fee of $100 million and
Roche Korea said Lunsumio (ingredient: mosunetuzumab), a CD20/CD3 bispecific antibody, has received approval from the Ministry of Food and Drug Safety to treat adult patients with recurrent or refractory follicular lymphoma (FL) who have undergone two or more systemic therapies.Lunsumio is the first